The Hol Picture

Our Insights on Real-World Evidence and Behavioral Health

Posts by:

Karthik Chandran

Karthik is Vice President and Commercial Lead for Holmusk’s flagship product, NeuroBlu. He brings over 12 years of experience in biopharma arena. Karthik previously worked at a boutique life sciences management consultancy, Blue Matter, where he led the company’s launch strategy practice on the East Coast. His work steered R&D, commercial, medical affairs, and market access teams at a variety of biopharma companies to prepare drugs for launch and to craft their go-to-market strategy. He is a research scientist by training, with a study focus in discovering novel drug targets for alcohol use disorder. Karthik received an MS from the Keck Graduate Institute in Biotechnology, and a BS from UCLA in Psychobiology.

a series of question marks and ideas represented as light bulbs

What questions can EHR data answer for biopharmaceutical teams?

The treatment of behavioral health conditions has historically been challenging. Despite the prevalent use of the DSM-V in clinical settings, clinicians lack a detailed and standardized vocabulary to discuss these conditions. This is due to a range of factors, from wide differences in disease presentation to stigma surrounding mental health conditions. The lack of standardized vocabulary has led to a subjective approach in treating these conditions, with each clinician relying on his or her own experience.

However, as more and more patients who are treated for behavioral health conditions are documented within an electronic health record (EHR) system, researchers now have a valuable tool for studying and improving the treatment of behavioral health conditions. By bringing together vast quantities of real-world data to understand how care and treatment are delivered in clinical practice, we can start building a set of standard definitions and objective measures for mental health conditions.

This is why we have created the NeuroBlu Database, in which we have extracted and organized EHR data from behavioral health clinics across the U.S. Our NeuroBlu data has thus far been leveraged by 5 of the top 15 biopharmaceutical companies with a behavioral health pipeline. These companies can benefit greatly from EHR-derived real-world data, particularly in the areas of research and development, medical affairs, and health economics and outcomes research (HEOR).

Read More